In HER2+ breast cancer cells, SIRT1, along with SIRT6, has been shown to modulate the acetylation status of the transcription factor FOXO3, thereby influencing sensitivity to lapatinib, another HER2-targeted therapy. This evidence concerns the gene ERBB2 and breast carcinoma.